Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (April 2025)
35 slides from Immunome's investor presentation, April 2025
Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation April 2025
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-and-
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company Anticipated 2025 Catalysts and a Foundation for Long-Term Corporate Vision Long-Term Success • Develop differentiated ADCs with a focus on first-in-class • Varegacestat, an oral, once-daily gamma secretase inhibitor targets for the treatment of desmoi
Slide 4: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) PRESID EN T & • Grew company to $2B+ revenue (2022) leading to $43B acquisition CH IEF EXEC UTIVE OFFIC ER • Led development of 4 FDA-approved therapeutics • Rais
Slide 5: Recent Business Development Activity Expanded Pipeline With Moderate Investment
Recent Business Development Activity Expanded Pipeline With Moderate Investment RECENT TRANSACTIONS 2024 4 Antibodies 2024 Varegacestat (AL102) 2025 IM-1021 Program & and AL101 ADC Platform 2024 2024 28 Antibodies 2024 2024 ANTIBODIES PRECLINICAL CLINICAL 5
Slide 6: Pipeline Overview
Pipeline Overview Candidate Mechanism of Action Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Varegacestat Phase 3 Topline Gamma Secretase Inhibitor (Formerly AL102) 2H25 IM-1021 ROR1 ADC Complete Dose Escalation First Patient In IM-3050 FAP RLT 2H25 IM-1617 ADC (Undisclos
Slide 7: Varegacestat
Varegacestat Phase 3 Oral, Once-Daily Gamma Secretase Inhibitor 7
Slide 8: Varegacestat May Address Substantial Unmet Patient Need in Desmoid Tumors
Varegacestat May Address Substantial Unmet Patient Need in Desmoid Tumors Desmoid Tumors Are Debilitating, Painful, and Varegacestat is a Potent Gamma Secretase Aggressive Inhibitor (GSI) • GSIs block the NOTCH pathway, which is believed to ~5,500-7,500 contribute to the growth of desmoid tumors Act
Slide 9: Varegacestat Data With Daily Dosing Shows Increased Response Compared to Nirogacestat
Varegacestat Data With Daily Dosing Shows Increased Response Compared to Nirogacestat Across All Measures • Varegacestat is being evaluated as an oral, ORR by RECIST once-daily GSI for the treatment of desmoid Evaluable tumors Varegacestat 1.2mg QD1 75% ITT Median ToT 16.6 months • Phase 2 RINGSIDE
Slide 10: Selected Phase 3 Dose of 1.2 mg Daily Shows Rapid Reduction in Tumor Burden
Selected Phase 3 Dose of 1.2 mg Daily Shows Rapid Reduction in Tumor Burden by Multiple Measures Phase 2 RINGSIDE Part A Data (Evaluable Patients) Source: Kasper B et al., ESMO Congress 2024_1766P (Cutoff Date – April 10, 2024) One patient previously reported as PR at ESMO subsequently progressed pr
Slide 11: Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class
Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class Study Population, n(%) Varegacestat, 1.2mg QD, (n=14) Nirogacestat 150mg BID (n=69) Any Grade Grade ≥3 Any Grade Grade ≥3 Diarrhoea 13 (92.8) 2 (14.3) 58 (84) 11 (16) Nausea 8 (57.1) – 37 (54) 1 (1) Fatigue 7 (50) – 35 (51) 2 (3) Alo
Slide 12: RINGSIDE Phase 3: Evaluating Safety and Efficacy in Progressing Desmoid Tumors
RINGSIDE Phase 3: Evaluating Safety and Efficacy in Progressing Desmoid Tumors Phase 3 Key Inclusion Criteria Endpoints • Relapsed/refractory or treatment- • Primary: PFS naïve, with PD (per RECIST) • Secondary: ORR & DOR by BICR, in last 12 months PROs, Safety • Age ≥12 • Exploratory: MRI T1 & T2,
Slide 13: IM-1021 ROR1 ADC
IM-1021 ROR1 ADC 13
Slide 14: ROR1 Is a Clinically Active ADC Target with Expression in Both Liquid and Solid Tumors
ROR1 Is a Clinically Active ADC Target with Expression in Both Liquid and Solid Tumors ROR1 MK-2140 Monotherapy Demonstrates • Receptor with oncofetal expression pattern, Potential of ROR1 in B-Cell Lymphoma2 including little or no normal tissue expression 1 45% • Expression on solid and liquid tumo
Slide 15: IM-1021: ROR1 ADC in Phase 1 Clinical Trials
IM-1021: ROR1 ADC in Phase 1 Clinical Trials IM-1021 Shows Superior Activity IM-1021 Design to MK-2140 in Jeko-1 MCL model • Antibody selected for ADC-specific properties 2500 • HC74 payload selected for properties that may enable efficacy in lymphoma and solid tumors Mean Tumor Volume (mm3) 2000 •
Slide 16: IM-1021's Payload, HC74, May Allow for Higher Clinical Dose, Increasing Therapeutic Index
IM-1021’s Payload, HC74, May Allow for Higher Clinical Dose, Increasing Therapeutic Index ADCs Containing TOP1 Inhibitors Achieve Higher ADCs with TOP1i Payloads Achieve Higher Clinical DAR, Allowing for Increased Payload Delivery Doses than ADCs with Microtubule Inhibitor Payloads Clinical Doses of
Slide 17: Significant Solid Tumor Opportunity for IM-1021
Significant Solid Tumor Opportunity for IM-1021 ROR1 is Expressed in Major Solid IM-1021 Achieves Tumor Regressions IM-1021 Achieves 8/8 CR at 2.5 Tumor Indications1 in TNBC (MDA-MB-468) Model mg/kg in NSCLC PDX Model Percent ROR1 Positive 1000 3,000 100% Vehicle Vehicle 900 IM-1021 2.5 mpk qw*3 IM-
Slide 18: Clinical Development Plan: Rapid Establishment of PoC Followed by Pivotal Studies
Clinical Development Plan: Rapid Establishment of PoC Followed by Pivotal Studies Across Multiple Indications Solid tumor expansion Criteria for selecting pivotal clinical Indications including NSCLC, breast study indications cancer, and other solid tumors • Compelling Phase 1 clinical outcomes Rapi
Slide 19: ADC Discovery Strategy
ADC Discovery Strategy 19
Slide 20: Immunome's Experienced Team is Positioned to Develop the Next Generation of Transformative ADCs
Immunome’s Experienced Team is Positioned to Develop the Next Generation of Transformative ADCs Exceptional ADC Expertise Rigorous Target Selection • Executive leadership with proven record of success • Deep understanding of target biology • ADC-focused discovery team with deep experience in ADC tar
Slide 21: Immunome's ADC Discovery Efforts Advanced 3 Novel Candidates into Development in 2024
Immunome’s ADC Discovery Efforts Advanced 3 Novel Candidates into Development in 2024 Differentiated Strategy ~1000 Targets • Focus on targets that have no approved ADCs and on Screened indications with substantial unmet need 40+ Targets • Prioritize definitive preclinical experiments, allowing Eval
Slide 22: The Majority of ADC Activity is Concentrated in a Small Number of Targets
The Majority of ADC Activity is Concentrated in a Small Number of Targets Top 10 Targets Account for 55% of Active Clinical ADC Programs Approved ADC No Approved ADC Active Clinical ADC Programs 40 24 16 15 12 10 10 9 8 7 HER-2 TROP-2 CLDN18.2 B7-H3 EGFR FRα HER-3 Nectin-4 c-MET TFR1 1.: Immunome An
Slide 23: Immunome's Proprietary TOP1 Inhibitor, HC74, Supports Development of ADCs for Novel Targets
Immunome’s Proprietary TOP1 Inhibitor, HC74, Supports Development of ADCs for Novel Targets TOP1 inhibitors are validated ADC payloads HC74 retains the validated TOP1 mechanism of Progression-Free action while showing properties superior to DXd Survival • Superior potency measured across 89 cell lin
Slide 24: Novel ADC Development Candidates
Novel ADC Development Candidates Three ADCs Against Undisclosed Targets Expressed in Solid Tumors 24
Slide 25: Novel ADC #1: Pursuing a Novel ADC Target with Multi-Indication Solid Tumor Potential
Novel ADC #1: Pursuing a Novel ADC Target with Multi-Indication Solid Tumor Potential Target Properties IM-1617’s Target is Expressed in Solid Tumor Indications with Significant Unmet Need • Tumor Expression: Major solid tumors including colorectal, ovarian, breast, and NSCLC • Non-Obvious Target: O
Slide 26: IM-1617 is a Potential First-in-Class ADC With Robust Preclinical Activity
IM-1617 is a Potential First-in-Class ADC With Robust Preclinical Activity IM-1617 Design Considerations In Vivo Activity • Antibody selected for Colorectal (HCT116) Esophageal (KYSE30) attributes that drive tumor 3000 Vehicle 3000 Vehicle Isotype ADC, 5 mg/kg Isotype ADC, 5 mg/kg Mean Tumor Volume
Slide 27: Novel ADC #2: Potential First-in-Class ADC Against a Novel Solid Tumor Receptor
Novel ADC #2: Potential First-in-Class ADC Against a Novel Solid Tumor Receptor Identifying a Unique Expression Profile IM-1340’s Target is Expressed in Neuroendocrine Tumors, Lung, and Prostate • Tumor Expression: Spans neuroendocrine tumors and carcinomas 100 Negative • Tumor Biology: Target known
Slide 28: IM-1340 is a Potential First-in-Class ADC that Shows Robust Efficacy in a Range of Models
IM-1340 is a Potential First-in-Class ADC that Shows Robust Efficacy in a Range of Models IM-1340 Design Considerations In Vivo Activity • High affinity antibody selected to SCLC (NCI-H1105) NSCLC (CALU6) drive efficacy 2000 Vehicle Isotype ADC, 5 mg/kg Vehicle Mean Tumor Volume (mm3) Mean Tumor Vol
Slide 29: Novel ADC #3: ADC Optimization Driven by Understanding Biology of a Known Target
Novel ADC #3: ADC Optimization Driven by Understanding Biology of a Known Target Revisiting a Target with Demonstrated Clinical Efficacy In Vivo Activity • IM-1335 shares a target with an ADC that showed clinical activity but was ultimately discontinued Solid Tumor Indication 2000 Vehicle • Immunome
Slide 30: Additional Discovery-Stage Candidates Demonstrate Solid Tumor Activity
Additional Discovery-Stage Candidates Demonstrate Solid Tumor Activity • Immunome has generated in vivo data In Vivo Preclinical Efficacy for Three Additional Candidates for over 15 distinct targets, with six SCLC (NCI-H446) Vehicle currently undergoing lead optimization 3000 Mean Tumor Volume (mm3)
Slide 31: IM-3050 FAP-Targeted Radioligand Therapy
IM-3050 FAP-Targeted Radioligand Therapy 31
Slide 32: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with Pan-Cancer Potential Fibroblast Activation Protein (FAP) is a cell surface FAP imaging shows high expression across protease with low expression in normal tissue 15 distinct tumor types • FAP is overexpressed on cancer-associated fibroblasts, the most common tumor
Slide 33: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened Immunome has systematically Immunome Approach selected a ligand, linker, albumin Example Structure: Proven structure used by Pluvicto and Lutathera to binding domain, and payload to Optimized linker deliver Lu-177 isot
Slide 34: IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential
IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG No Weight Loss Observed Potential Best-in-Class Model Characteristics Vehicle Vehicle Sub-nanomolar affinity 1200 120 IM-3050, 150 mCi IM-3050, 15
Slide 35: Building the Foundation of the Next Transformative ADC Company
Building the Foundation of the Next Transformative ADC Company • Fully enrolled Phase 3 trial for varegacestat • Clinical and IND-stage programs with best-in-class or first-in-class potential: • IM-1021: ROR1 ADC • IM-3050: FAP RLT • Three novel solid-tumor targeted ADCs in preclinical development: